"When one has a decreased appetite, they may think that they do not need any insulin, and if [insulin is] held or dosed sub-optimally, it could theoretically increase the risk of DKA," said Dr
Generic dosing

For patients with severe fibromyalgia fatigue, this should be anticipated and managed with adequate nutrition and rest Hypoglycemia in non-diabetic patients: Tirzepatide's glucose-dependent insulin secretion minimizes hypoglycemia risk, but patients taking it with other glucose-lowering medications should be monitored Who Might Benefit Tirzepatide may be most valuable for fibromyalgia patients who: Have documented insulin resistance or metabolic syndrome alongside their fibromyalgia, where tirzepatide can address both conditions simultaneously Have BMI of 30+ (or 27+ with comorbidity), meeting prescribing criteria for Zepbound or Mounjaro Experience fibromyalgia symptoms that worsened significantly with weight gain, suggesting a metabolic contribution to their pain Haven't achieved adequate relief from traditional fibromyalgia medications alone Are motivated to combine pharmacotherapy with exercise but are currently limited by pain and deconditioning Have tried GLP-1-only medications (semaglutide) with incomplete benefit, warranting a dual-mechanism approach How to Talk to Your Doctor Presenting tirzepatide as a fibromyalgia-relevant treatment requires connecting the metabolic evidence to your clinical picture: Request metabolic testing if you haven't had it recently: fasting insulin, HOMA-IR, HbA1c, lipid panel, and hsCRP

The drug begins with 0.25mg per week in the first month, and then moves slowly to 1mg or 2.4 mg depending on the individual response and tolerability